These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24913512)

  • 1. A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia.
    Bryant A; Sheppard D; Sabloff M; Delbaere M; Maze R; Allan D; Atkins H; Bence-Bruckler I; Faught C; Huebsch L; Tay J; Zanke B; Bredeson C
    Leuk Lymphoma; 2015 Jan; 56(1):135-40. PubMed ID: 24913512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
    Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
    Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
    Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
    Stahl M; Giblin G; Liu Y; Winer ES; Garcia JS; Chen E; Wadleigh M; Ling K; Lindsley RC; Shimony S; Copson K; Charles A; DeAngelo DJ; Stone RM; Nohria A; Luskin MR
    Leuk Res; 2023 Sep; 132():107351. PubMed ID: 37451200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
    Chia PL; Chiang K; Snyder R; Dowling A
    J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
    Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
    J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
    Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
    J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
    Valcárcel D; Montesinos P; Sánchez-Ortega I; Brunet S; Esteve J; Martínez-Cuadrón D; Ribera JM; Tormo M; Bueno J; Duarte R; Llorente A; Torres JP; Guardia R; Sanz MA; Sierra AJ;
    Cancer; 2012 Jan; 118(2):410-7. PubMed ID: 21717435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
    Wenzell CM; Gallagher EM; Earl M; Yeh JY; Kusick KN; Advani AS; Kalaycio ME; Mukherjee S; Tiu RV; Maciejewski JP; Sekeres MA
    Am J Hematol; 2013 Oct; 88(10):906-9. PubMed ID: 23828018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience.
    Tasaki T; Yamauchi T; Matsuda Y; Takai M; Ookura M; Lee S; Tai K; Ikegaya S; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2014 Oct; 34(10):5631-6. PubMed ID: 25275066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.
    Lim MJ; Agha A; Im A; Raptis A; Hou JZ; Boyiadzis M; Sehgal AR; Redner RL; Dorritie K; Marks SS; Agha ME; Lim SH
    Hematol Oncol; 2018 Apr; 36(2):495-497. PubMed ID: 28664979
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Hershenfeld SA; Atenafu EG; Chan S; Gupta V; Maze D; Schuh A; Sibai H; Yee K; Schimmer AD
    Acta Haematol; 2023; 146(5):366-372. PubMed ID: 37315549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
    Miyawaki S
    Int J Hematol; 2017 Sep; 106(3):310-325. PubMed ID: 28786079
    [No Abstract]   [Full Text] [Related]  

  • 17. Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
    Zhong LY; Li QH; Huang ZL; Lin W; Lu ZS; Weng JY; Wu SJ; Du X
    Ai Zheng; 2009 Jun; 28(6):619-25. PubMed ID: 19635200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
    Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
    Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis.
    Shaikh AY; Suryadevara S; Tripathi A; Ahmed M; Kane JL; Escobar J; Cerny J; Nath R; McManus DD; Shih J; McGuiness ME; Tighe DA; Meyer TE; Ramanathan M; Aurigemma GP
    Echocardiography; 2016 Aug; 33(8):1166-77. PubMed ID: 27109429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
    Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
    Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.